Alzheimer's disease protein aggregate degrader program
preclinicaldrug program · medium · Tue Jun 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat Alzheimer's disease by selectively degrading disease-causing aggregated proteins, including pathological tau-related aggregates.
TRIM21-recruiting small molecule targeted protein degradation of aggregated protein targets through the ubiquitin-proteasome system.
Seed financing expanded to $47 million to advance TRIMTECH's targeted protein degradation pipeline for neurodegenerative diseases.
Filtered publications include aggregate-selective removal of pathological tau by clustering-activated degraders and tau-related TRIM21 immunotherapy/degradation evidence.
Huntington's disease protein aggregate degrader program
preclinicaldrug program · medium · Tue Jun 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat Huntington's disease by selectively degrading disease-causing aggregated protein targets.
TRIM21-recruiting small molecule targeted protein degradation via TRIMTAC/TRIMGLUE molecules and the ubiquitin-proteasome system.
Seed financing expanded to $47 million to advance TRIMTECH's targeted protein degradation portfolio for neurodegenerative diseases including Huntington's disease.
Parkinson's disease protein aggregate degrader program
preclinicaldrug program · medium · Tue Jun 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat Parkinson's disease by selectively degrading disease-causing aggregated protein targets.
TRIM21-recruiting small molecule targeted protein degradation via TRIMTAC/TRIMGLUE molecules and the ubiquitin-proteasome system.
Seed financing expanded to $47 million to advance TRIMTECH's targeted protein degradation portfolio for neurodegenerative diseases including Parkinson's disease.
TRIMGLUE targeted protein degradation portfolio
preclinicalplatform · high · Tue Jun 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop small molecule degraders that recruit TRIM21 to disease-causing aggregated protein targets for selective degradation in neurodegenerative and inflammatory disorders.
Small molecule TRIM21-recruiting targeted protein degradation using TRIMGLUE molecules and the ubiquitin-proteasome system.
Additional $14 million seed investment announced to further develop the TRIMTAC and TRIMGLUE targeted protein degradation portfolio, bringing total seed funding to $47 million.
Company materials describe TRIMGLUE as part of the TRIM21-recruiting degrader portfolio; supplied materials do not provide separate TRIMGLUE-specific efficacy results.
TRIMTAC targeted protein degradation portfolio
preclinicalplatform · high · Tue Jun 23 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop small molecule targeted protein degraders that recruit TRIM21 to selectively remove disease-causing aggregated protein targets, with application to neurodegenerative and inflammatory disorders.
Small molecule TRIM21-recruiting targeted protein degradation using TRIMTAC molecules to induce ubiquitin-proteasome degradation of aggregated proteins.
Additional $14 million seed investment announced to further develop the TRIMTAC and TRIMGLUE targeted protein degradation portfolio, bringing total seed funding to $47 million.
Preclinical/publication evidence supports aggregate-selective removal of pathological tau and related TRIM21-mediated degradation biology.
